Buffered Penicillin G Potassium for Injection, USP may be given intravenously or intramuscularly. The usual dose recommendations are as follows:
| CLINICAL INDICATION | DOSAGE | |
|---|---|---|
| ||
Serious infections due to susceptible strains of streptococci (including S. pneumoniae) | 12 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4–6 hours. | |
Serious infections due to susceptible strains of staphylococci | 5 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4–6 hours. | |
Anthrax | Minimum of 8 million units/day in divided doses every 6 hours. Higher doses may be required depending on susceptibility of organism. | |
Actinomycosis | ||
Clostridial infections |
| |
Diphtheria (adjunctive therapy to antitoxin and for the prevention of the carrier state) | 2 to 3 million units/day in divided doses for 10–12 days* | |
Erysipelothrix endocarditis | 12 to 20 million units/day for 4–6 weeks* | |
Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) | 5 to 10 million units/day* | |
Listeria infections |
| |
Pasteurella infections including bacteremia and meningitis | 4 to 6 million units/day for 2 weeks* | |
Haverhill fever; Rat-bite fever | 12 to 20 million units/day for 3–4 weeks* | |
Disseminated gonococcal infections, such as meningitis, endocarditis, arthritis, etc., caused by penicillin – susceptible organisms | 10 million units/day*; duration depends on the type of infection | |
Syphilis (neurosyphilis) | 12 to 24 million units/day, as 2–4 MU every 4 hours for 10–14 days; many experts recommend additional therapy with Benzathine PCN G 2.4 MU IM weekly for 3 doses after completion of IV therapy | |
Meningococcal meningitis and/or septicemia | 24 million units/day as 2 million units every 2 hours | |
This product should not be administered to patients requiring less than one million units per dose (see Precautions-Pediatric Use).
| CLINICAL INDICATION | DOSAGE | |
|---|---|---|
Serious infections, such as pneumonia and endocarditis, due to susceptible strains of streptococci (including S. pneumoniae) and meningococcus | 150,000–300,000 units/kg/day divided in equal doses every 4–6 hours; duration depends on infecting organism and type of infection | |
Meningitis caused by susceptible strains of pneumococcus and meningococcus | 250,000 units/kg/day divided in equal doses every 4 hours for 7–14 days depending on the infecting organism (maximum dose of 12–20 million units/day) | |
Disseminated Gonococcal Infections (penicillin-susceptible strains) | Weight less than 45 kg: | |
Arthritis | 100,000 units/kg/day in 4 equally divided doses for 7–10 days | |
Meningitis | 250,000 units/kg/day in equal doses every 4 hours for 10–14 days | |
Endocarditis | 250,000 units/kg/day in equal doses every 4 hours for 4 weeks | |
Arthritis, meningitis, endocarditis | Weight 45 kg or greater: 10 million units/day in equally divided doses with the duration of therapy depending on the type of infection | |
Syphilis (congenital and neurosyphilis) after the newborn period | 200,000–300,000 units/kg/day (administered as 50,000 units/kg every 4–6 hours) for 10–14 days | |
Diphtheria (adjunctive therapy to antitoxin and for prevention of the carrier state) | 150,000–250,000 units/kg/day in equal doses every 6 hours for 7–10 days | |
Rat-bite fever; Haverhill fever (with endocarditis caused by S. moniliformis) | 150,000–250,000 units/kg/day in equal doses every 4 hours for 4 weeks |
Penicillin G is relatively nontoxic, and dosage adjustments are generally required only in cases of severe renal impairment. The recommended dosage regimens are as follows:
Creatinine clearance less than 10 mL/min/1.73m2; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 8–10 hours.
Uremic patients with a creatinine clearance greater than 10 mL/min/1.73m2; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 4–5 hours. Additional dosage modification should be made in patients with hepatic disease and renal impairment.
For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for Group A β-hemolytic streptococcal infections should be maintained for at least 10 days to reduce the risk of rheumatic fever.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
The following table shows the amount of solvent required for solution of various concentrations:
| Approx. Desired Concentration (units/mL) | Volume (mL) Solvent for Vial of 5,000,000 units | Infusion Only Volume (mL) Solvent for Vial of 20,000,000 units | |||
|---|---|---|---|---|---|
50,000 | – | – | |||
100,000 | – | – | |||
250,000 | 18.2 | 75.0 | |||
500,000 | 8.2 | 33.0 | |||
1,000,000 | 3.2 | 11.5 |
When the required volume of solvent is greater than the capacity of the vial, the penicillin can be dissolved by first injecting only a portion of the solvent into the vial, then withdrawing the resultant solution and combining it with the remainder of the solvent in a larger sterile container.
Buffered Pfizerpen (Penicillin G Potassium for Injection, USP) is highly water soluble. It may be dissolved in small amounts of Water for Injection, or Sterile Isotonic Sodium Chloride Solution for Parenteral Use. All solutions should be stored in a refrigerator. When refrigerated, penicillin solutions may be stored for seven days without significant loss of potency.
Buffered Pfizerpen for Injection may be given intramuscularly or by continuous intravenous infusion for dosages of 500,000, 1,000,000, or 5,000,000 units. It is also suitable for intrapleural, intraarticular, and other local instillations.
THE 20,000,000 UNIT DOSAGE MAY BE ADMINISTERED BY INTRAVENOUS INFUSION ONLY.
Keep total volume of injection small. The intramuscular route is the preferred route of administration. Solutions containing up to 100,000 units of penicillin per mL of diluent may be used with a minimum of discomfort. Greater concentration of penicillin G per mL is physically possible and may be employed where therapy demands. When large dosages are required, it may be advisable to administer aqueous solutions of penicillin by means of continuous intravenous infusion.
Determine the volume of fluid and rate of its administration required by the patient in a 24 hour period in the usual manner for fluid therapy, and add the appropriate daily dosage of penicillin to this fluid. For example, if an adult patient requires 2 liters of fluid in 24 hours and a daily dosage of 10 million units of penicillin, add 5 million units to 1 liter and adjust the rate of flow so the liter will be infused in 12 hours.
If fluid is aspirated, give infusion in a volume equal to ¼ or ½ the amount of fluid aspirated, otherwise, prepare as for intramuscular injection.
The intrathecal use of penicillin in meningitis must be highly individualized. It should be employed only with full consideration of the possible irritating effects of penicillin when used by this route. The preferred route of therapy in bacterial meningitides is intravenous, supplemented by intramuscular injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Sterile solution may be left in refrigerator for one week without significant loss of potency.
Buffered Penicillin G Potassium for Injection, USP may be given intravenously or intramuscularly. The usual dose recommendations are as follows:
| CLINICAL INDICATION | DOSAGE | |
|---|---|---|
| ||
Serious infections due to susceptible strains of streptococci (including S. pneumoniae) | 12 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4–6 hours. | |
Serious infections due to susceptible strains of staphylococci | 5 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4–6 hours. | |
Anthrax | Minimum of 8 million units/day in divided doses every 6 hours. Higher doses may be required depending on susceptibility of organism. | |
Actinomycosis | ||
Clostridial infections |
| |
Diphtheria (adjunctive therapy to antitoxin and for the prevention of the carrier state) | 2 to 3 million units/day in divided doses for 10–12 days* | |
Erysipelothrix endocarditis | 12 to 20 million units/day for 4–6 weeks* | |
Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) | 5 to 10 million units/day* | |
Listeria infections |
| |
Pasteurella infections including bacteremia and meningitis | 4 to 6 million units/day for 2 weeks* | |
Haverhill fever; Rat-bite fever | 12 to 20 million units/day for 3–4 weeks* | |
Disseminated gonococcal infections, such as meningitis, endocarditis, arthritis, etc., caused by penicillin – susceptible organisms | 10 million units/day*; duration depends on the type of infection | |
Syphilis (neurosyphilis) | 12 to 24 million units/day, as 2–4 MU every 4 hours for 10–14 days; many experts recommend additional therapy with Benzathine PCN G 2.4 MU IM weekly for 3 doses after completion of IV therapy | |
Meningococcal meningitis and/or septicemia | 24 million units/day as 2 million units every 2 hours | |
This product should not be administered to patients requiring less than one million units per dose (see Precautions-Pediatric Use).
| CLINICAL INDICATION | DOSAGE | |
|---|---|---|
Serious infections, such as pneumonia and endocarditis, due to susceptible strains of streptococci (including S. pneumoniae) and meningococcus | 150,000–300,000 units/kg/day divided in equal doses every 4–6 hours; duration depends on infecting organism and type of infection | |
Meningitis caused by susceptible strains of pneumococcus and meningococcus | 250,000 units/kg/day divided in equal doses every 4 hours for 7–14 days depending on the infecting organism (maximum dose of 12–20 million units/day) | |
Disseminated Gonococcal Infections (penicillin-susceptible strains) | Weight less than 45 kg: | |
Arthritis | 100,000 units/kg/day in 4 equally divided doses for 7–10 days | |
Meningitis | 250,000 units/kg/day in equal doses every 4 hours for 10–14 days | |
Endocarditis | 250,000 units/kg/day in equal doses every 4 hours for 4 weeks | |
Arthritis, meningitis, endocarditis | Weight 45 kg or greater: 10 million units/day in equally divided doses with the duration of therapy depending on the type of infection | |
Syphilis (congenital and neurosyphilis) after the newborn period | 200,000–300,000 units/kg/day (administered as 50,000 units/kg every 4–6 hours) for 10–14 days | |
Diphtheria (adjunctive therapy to antitoxin and for prevention of the carrier state) | 150,000–250,000 units/kg/day in equal doses every 6 hours for 7–10 days | |
Rat-bite fever; Haverhill fever (with endocarditis caused by S. moniliformis) | 150,000–250,000 units/kg/day in equal doses every 4 hours for 4 weeks |
Penicillin G is relatively nontoxic, and dosage adjustments are generally required only in cases of severe renal impairment. The recommended dosage regimens are as follows:
Creatinine clearance less than 10 mL/min/1.73m2; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 8–10 hours.
Uremic patients with a creatinine clearance greater than 10 mL/min/1.73m2; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 4–5 hours. Additional dosage modification should be made in patients with hepatic disease and renal impairment.
For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for Group A β-hemolytic streptococcal infections should be maintained for at least 10 days to reduce the risk of rheumatic fever.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
The following table shows the amount of solvent required for solution of various concentrations:
| Approx. Desired Concentration (units/mL) | Volume (mL) Solvent for Vial of 5,000,000 units | Infusion Only Volume (mL) Solvent for Vial of 20,000,000 units | |||
|---|---|---|---|---|---|
50,000 | – | – | |||
100,000 | – | – | |||
250,000 | 18.2 | 75.0 | |||
500,000 | 8.2 | 33.0 | |||
1,000,000 | 3.2 | 11.5 |
When the required volume of solvent is greater than the capacity of the vial, the penicillin can be dissolved by first injecting only a portion of the solvent into the vial, then withdrawing the resultant solution and combining it with the remainder of the solvent in a larger sterile container.
Buffered Pfizerpen (Penicillin G Potassium for Injection, USP) is highly water soluble. It may be dissolved in small amounts of Water for Injection, or Sterile Isotonic Sodium Chloride Solution for Parenteral Use. All solutions should be stored in a refrigerator. When refrigerated, penicillin solutions may be stored for seven days without significant loss of potency.
Buffered Pfizerpen for Injection may be given intramuscularly or by continuous intravenous infusion for dosages of 500,000, 1,000,000, or 5,000,000 units. It is also suitable for intrapleural, intraarticular, and other local instillations.
THE 20,000,000 UNIT DOSAGE MAY BE ADMINISTERED BY INTRAVENOUS INFUSION ONLY.
Keep total volume of injection small. The intramuscular route is the preferred route of administration. Solutions containing up to 100,000 units of penicillin per mL of diluent may be used with a minimum of discomfort. Greater concentration of penicillin G per mL is physically possible and may be employed where therapy demands. When large dosages are required, it may be advisable to administer aqueous solutions of penicillin by means of continuous intravenous infusion.
Determine the volume of fluid and rate of its administration required by the patient in a 24 hour period in the usual manner for fluid therapy, and add the appropriate daily dosage of penicillin to this fluid. For example, if an adult patient requires 2 liters of fluid in 24 hours and a daily dosage of 10 million units of penicillin, add 5 million units to 1 liter and adjust the rate of flow so the liter will be infused in 12 hours.
If fluid is aspirated, give infusion in a volume equal to ¼ or ½ the amount of fluid aspirated, otherwise, prepare as for intramuscular injection.
The intrathecal use of penicillin in meningitis must be highly individualized. It should be employed only with full consideration of the possible irritating effects of penicillin when used by this route. The preferred route of therapy in bacterial meningitides is intravenous, supplemented by intramuscular injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Sterile solution may be left in refrigerator for one week without significant loss of potency.
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.